Actively Recruiting
Observational Study on Clinical Outcomes in RelapsedRefractory Multiple Myeloma Patients Treated with Teclistamab and Talquetamab Outside Clinical Trials
Led by Janssen-Cilag Ltd. · Updated on 2026-08-28
900
Participants Needed
68
Research Sites
3 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are collecting and analyzing medical records from patients with relapsed or refractory multiple myeloma RRMM who have received the treatments teclistamab or talquetamab outside of clinical trials. The study aims to describe how these treatments are used and their effects in real-world settings, focusing on patients who received these therapies during specific time periods. This observational study is sponsored by Janssen-Cilag Ltd. Participants are grouped based on when they first received teclistamab or talquetamab, covering periods up to December 2025 for teclistamab and December 2023 for talquetamab. The study does not involve administering treatments directly but collects retrospective data from medical records to describe treatment use. Data from multiple cohorts are compiled to understand outcomes following these T-cell redirector therapies. Participants medical records are reviewed to gather information on baseline characteristics, response rates, survival, and safety management over up to 40 months. Researchers track overall response rate, time to response, duration of response, minimal residual disease, overall survival, progression-free survival, and time to next treatment. The study also assesses how the treatments are managed in real-world practice, with no direct interventions or visits required from participants during this observational study.
CONDITIONS
Brief Title
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here